Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy

Pigment Cell and Melanoma Research

Volumn 23, Issue 5, 2010, Pages 580-581

  Gajewski, Thomas F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DACARBAZINE; INTERLEUKIN 2; IPILIMUMAB; MONOCLONAL ANTIBODY; PEPTIDE VACCINE; TICILIMUMAB; VACCINE;

CANCER SURVIVAL; CELL DEATH; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; MELANOMA; METASTASIS; REGULATORY T LYMPHOCYTE; SHORT SURVEY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; MELANOMA; SKIN NEOPLASMS;

EID: 77956327518     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2010.00737.x     Document Type: Short Survey

References (4)

1. Camacho, L.H., Antonia, S., Sosman, J. et al. (2009). Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27, 1075 1081.
2. Gajewski, T.F., Meng, Y., Blank, C. et al. (2006). Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213, 131 145.
3. Harlin, H., Meng, Y., Peterson, A.C. et al. (2009). Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69, 3077 3085.
4. O'Day, S.J., Maio, M., Chiarion-Sileni, V. et al. (2010). Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann. Oncol. doi: 10.1093/annonc/mdq013.